Stifel Nicolaus Believes Atricure (ATRC) Won’t Stop Here


In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Atricure (NASDAQ: ATRC), with a price target of $34. The company’s shares opened today at $31.85, close to its 52-week high of $33.01.

According to TipRanks.com, Wise is a 5-star analyst with an average return of 15.8% and a 73.4% success rate. Wise covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Boston Scientific Corp, and Intuitive Surgical.

Currently, the analyst consensus on Atricure is a Strong Buy with an average price target of $34.60, representing an 8.6% upside. In a report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $37 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $33.01 and a one-year low of $14.88. Currently, Atricure has an average volume of 171.4K.

Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2018, Elizabeth Krell, a Director at ATRC sold 10,000 shares for a total of $228,200.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AtriCure, Inc. engages provision of treatment of atrial fibrillation and left atrial appendage. It operates through the following geographical segments: United States, Europe, Asia, and Other International.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts